Sanofi-aventis video Q&A: CFO Jérôme Contamine Comments on Results for Q3 2010

PARIS PARIS--(BUSINESS WIRE)-- Sanofi-aventis (Paris:SAN) (NYSE:SNY), one of the world’s largest diversified healthcare companies, reports results for the third-quarter of 2010. Jérôme Contamine, Chief Financial Officer of sanofi-aventis, comments on earnings and outlook.

Click to watch the video:

http://www.eurobusinessmedia.com/Sanofi-aventis-video-Q-A-CFO-Jerome-Contamine-comments-on-Q3-2010-results

Topics covered in the interview include:

  • Q3 earnings
  • 2010 full year guidance
  • Lovenox®
  • New launches (Jevtana®, Multaq®)
  • Seasonal flu vaccines
  • Eloxatin®
  • lixisenatide for Diabetes
  • teriflunomide for Multiple Sclerosis
  • US healthcare reform and EU price cuts
  • Cost savings
  • Patent cliff

About sanofi-aventis:

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Company website: http://en.sanofi-aventis.com/home.asp



CONTACT:

Investor Relations : [email protected]
or
Media Relations : [email protected]

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.